» Articles » PMID: 20201245

[Effect of Memantine Treatment on Patients with Moderate-to-severe Alzheimer's Disease Treated with Donepezil]

Overview
Date 2010 Mar 6
PMID 20201245
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Investigating the behavioral and cognitive effect of memantine in moderate to severe patients with Alzheimer's disease receiving donepezil.

Material And Method: 43 patients were enrolled in this prospective, randomized, parallel group study. There were no significant imbalances between the treatment groups in demographic and baseline clinical characteristics. Cognitive and global measures were collected at baseline and at the end of weeks 4, 8, 12 and 24. Behavioral measures were collected at baseline, at the end of week 12 and at week 24.

Results: Memantine--treated patients showed significantly less deterioration in their functionality. Of patients who exhibited agitation/aggression at baseline, those treated with memantine and donepezil showed significant reduction of symptoms compared with donepezil--treated patients.

Conclusions: Treatment with memantine was well tolerated and reduced agitation/aggression, irritability, and appetite eating disturbances in patients who were agitated at baseline and delazed its emergence in those who were free of agitation at baseline.

Citing Articles

Memantine for dementia.

McShane R, Westby M, Roberts E, Minakaran N, Schneider L, Farrimond L Cochrane Database Syst Rev. 2019; 3:CD003154.

PMID: 30891742 PMC: 6425228. DOI: 10.1002/14651858.CD003154.pub6.


Present Algorithms and Future Treatments for Alzheimer's Disease.

Grossberg G, Tong G, Burke A, Tariot P J Alzheimers Dis. 2019; 67(4):1157-1171.

PMID: 30741683 PMC: 6484274. DOI: 10.3233/JAD-180903.


Alzheimer's Disease Risk and Progression: The Role of Nutritional Supplements and their Effect on Drug Therapy Outcome.

Giulietti A, Vignini A, Nanetti L, Mazzanti L, Di Primio R, Salvolini E Curr Neuropharmacol. 2015; 14(2):177-90.

PMID: 26415975 PMC: 4825948. DOI: 10.2174/1570159x13666150928155321.


Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis.

Matsunaga S, Kishi T, Iwata N Int J Neuropsychopharmacol. 2014; 18(5).

PMID: 25548104 PMC: 4376554. DOI: 10.1093/ijnp/pyu115.


NMDA Neurotransmission Dysfunction in Behavioral and Psychological Symptoms of Alzheimer's Disease.

Huang Y, Lin C, Lane H, Tsai G Curr Neuropharmacol. 2013; 10(3):272-85.

PMID: 23450042 PMC: 3468881. DOI: 10.2174/157015912803217288.